Published in TB and Outbreaks Week, November 1st, 2005
These efforts include the launch of a major educational campaign to raise clinician awareness of the changing landscape of C. difficile-associated disease. ViroPharma commercializes Vancocin, which is indicated for the treatment of antibiotic-associated pseudomembranous colitis caused by C. difficile.
New information on an emerging strain of C. difficile was published in the September 24 edition of the Lancet (2005;366:1079-84). The...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week